Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Feb;43(1):120-124.
doi: 10.1007/s13410-022-01116-w. Epub 2022 Jul 16.

Brentuximab vedotin-associated diabetic ketoacidosis: a case report

Affiliations
Case Reports

Brentuximab vedotin-associated diabetic ketoacidosis: a case report

Damla Köksalan et al. Int J Diabetes Dev Ctries. 2023 Feb.

Abstract

Background: Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes mellitus (DM). It is characterized by hyperglycemia, metabolic acidosis, and ketonemia. Fortunately, drug-induced hyperglycemias are usually mild and not life-threatening. However, rarely some cases may present with ketoacidosis. In this case report, we aimed to present a brentuximab vedotin (BV) associated with DKA.

Case presentation: A 23-year-old Caucasian man presented with abdominal pain, nausea, and vomiting for 1-2 weeks. The patient had a previous diagnosis of Hodgkin's lymphoma and primer hypothyroidism. He is using levothyroxine 150 μg per day and received BV treatment for Hodgkin lymphoma (HL) 10 days ago. No steroid treatment was administered for premedication before BV. Except for obesity, all system examinations are normal. There were no signs of any infection. Laboratory data revealed hyperglycemia, metabolic acidosis, and ketonemia. The patient was admitted to the service with a diagnosis of DKA. After the patient was admitted to our clinic, insulin treatment and hydration started immediately. Despite the insulin infusion reaching 1700 units per day, the patient's diabetic ketoacidosis extended to 1 week. Anti-insulin, anti-glutamic acid decarboxylase, and islet cell autoantibodies were negative, which were checked to exclude type 1 DM. Fasting C-peptide was 28 ng/mL (normal range, 0.9-7.1 ng/mL). With all these, the diabetic ketoacidosis status of the patient was evaluated as a BV side effect.

Conclusion: This patient is a rare case of BV-associated DKA. It is very important to know this relationship since BV treatment has turned into a standard treatment for relapsed Hodgkin lymphoma. Our case highlights that this diagnosis should be kept in mind as a complication of each dose of BV administration.

Keywords: Brentuximab vedotin; Diabetic ketoacidosis; Drug-induced hyperglycemia.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Normoglycemic cycle
Fig. 2
Fig. 2
Insulin requirement

Similar articles

Cited by

References

    1. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism: Clinical and Experimental. 2016;65:507–521. doi: 10.1016/j.metabol.2015.12.007. - DOI - PubMed
    1. Ansell SM. Hodgkin lymphoma: diagnosis and treatment. In: Mayo Clinic Proceedings. Elsevier Ltd; 2015. Hodgkin Lymphoma: Diagnosis and Treatment; pp. 1574–1583. - PubMed
    1. Makita S, Maruyama D, Tobinai K. Safety and efficacy of brentuximab vedotin in the treatment of classic Hodgkin lymphoma. OncoTargets and Therapy. 2020;13:5993–6009. doi: 10.2147/OTT.S193951. - DOI - PMC - PubMed
    1. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clinical Cancer Research. 2011;17:6428–36. 10.1158/1078-0432.CCR-11-0488 - PubMed
    1. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21. 10.1056/NEJMoa1002965 - PubMed

Publication types

LinkOut - more resources